These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 27350621)

  • 21. [Intra-leukocyte cystine in cystinosis treated with cysteamine].
    Ged C; Jean G; Tete MJ; Broyer M; Kamoun P
    Ann Biol Clin (Paris); 1991; 49(9):482-6. PubMed ID: 1789502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice.
    Ariceta G; Santos F; López Muñiz A; Hermida A; Matoses ML; Ventura A; Martin-Moreno PL; González E; Acuña L; Giner E; Vara J
    Clin Kidney J; 2024 Apr; 17(4):sfae049. PubMed ID: 38633840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cysteamine in the treatment of cystinosis in children. In vitro and in vivo studies].
    Louis JJ; Guibaud P; Dumoulin R; Parchoux B; Zabot MT; Bureau J; Baltassat P; Frederich A; Larbre F
    Pediatrie; 1984 Dec; 39(8):619-33. PubMed ID: 6535971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystinosis: a new perspective.
    Veys KR; Besouw MT; Pinxten AM; Dyck MV; Casteels I; Levtchenko EN
    Acta Clin Belg; 2016 Jun; 71(3):131-7. PubMed ID: 25560059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystinosis: clinical presentation, pathogenesis and treatment.
    Ivanova E; De Leo MG; De Matteis MA; Levtchenko E
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():176-84. PubMed ID: 25345100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
    Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.
    Levtchenko EN; van Dael CM; de Graaf-Hess AC; Wilmer MJ; van den Heuvel LP; Monnens LA; Blom HJ
    Pediatr Nephrol; 2006 Jan; 21(1):110-3. PubMed ID: 16252107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephropathic cystinosis in children: An overlooked disease.
    Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
    Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
    Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cysteamine therapy in nephropathic cystinosis.
    Yudkoff M; Foreman JW; Segal S
    N Engl J Med; 1981 Jan; 304(3):141-5. PubMed ID: 7442733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
    Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
    BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
    Belldina EB; Huang MY; Schneider JA; Brundage RC; Tracy TS
    Br J Clin Pharmacol; 2003 Nov; 56(5):520-5. PubMed ID: 14651726
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.